Results 61 to 70 of about 5,745,585 (307)

Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell differentiation from pluripotent stem cells [PDF]

, 2015
© 2015 Macmillan Publishers Limited. All rights reserved. microRNA-34a (miR-34a) and sirtuin 1 (SirT1) have been extensively studied in tumour biology and longevityaging, but little is known about their functional roles in smooth muscle cell (SMC ...
L A Luong, Wen, G., Q Chen, Luong, LA, Q Xiao, Zhu, J, Zhu, J., Chen, Q, Y Huang, Luong, L. A., Zhang, L., Ye, S., H Zhao, G Wen, Wang, W, L Zhang, Xu, Q., Yu, X., Wen, G, Xiao, Q, Ye, S, Huang, Y, Q Xu, Zhao, H, X Yu, Huang, Y., Xu, Q, W Wang, Chen, Q., J Zhu, Yu, X, Zhang, L, Wang, W., Xiao, Q., Zhao, H., S Ye   +35 more
core   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation [PDF]

, 2012
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marrow transplantation (BMT) characterized by an autoimmune-type reaction in various organs.
Yumi Matsuzaki, Yoko Ogawa, Shigeto Shimmura, Yo Mabuchi, Sadafumi Suzuki, Yutaka Kawakami, Shinichiro Okamoto, Hideyuki Okano, Takaaki Inaba, Satoru Morikawa, Saori Yaguchi, Kazuo Tsubota, Tomonori Yaguchi   +12 more
core  

Ontological Differences in First Compared to Third Trimester Human Fetal Placental Chorionic Stem Cells [PDF]

, 2012
Human mesenchymal stromal/stem cells (MSC) isolated from fetal tissues hold promise for use in tissue engineering applications and cell-based therapies, but their collection is restricted ethically and technically.
Vanleene, Maximilien, George Bou-Gharios (139817), Moschidou Dafni, Gemma N Jones, Maximilien Vanleene (139811), George Bou-Gharios, Puga-Iglesias, Tamara-Isabel, Katarzyna Kuleszewicz, Sandra J. Shefelbine (139814), David, AL, Shefelbine, Sandra J., Fisk, NM, David Anna L., Moschidou, Dafni, Shefelbine Sandra J., Guillot, Pascale V., Bou-Gharios George, Gemma N. Jones (139797), Maximilien Vanleene, Fisk Nicholas M., Nicholas M Fisk, Shefelbine, SJ, De Coppi, Paolo, Puga-Iglesias, TI, Puga-Iglesias Tamara-Isabel, Katarzyna Kuleszewicz (139808), Paolo De Coppi (118582), Jones Gemma N., Bou-Gharios, G, Pascale V. Guillot (139827), Kuleszewicz Katarzyna, Anna L David, Vanleene, M, Kuleszewicz, K, David, Anna L., Sandra J Shefelbine, Fisk, Nicholas M., Dafni Moschidou, Paolo De Coppi, Bou-Gharios, George, Tamara-Isabel Puga-Iglesias, Pascale V Guillot, Jones, GN, Tamara-Isabel Puga-Iglesias (139805), Guillot, PV, De Coppi Paolo, Fisk, NM ; https://orcid.org/, Jones, Gemma N., Dafni Moschidou (139801), Guillot Pascale V., Kuleszewicz, Katarzyna, Moschidou, D, Vanleene Maximilien, Nicholas M. Fisk (139820), De Coppi, P, Anna L. David (139823)   +55 more
core   +1 more source

Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells

Journal of Tissue Engineering, 2014
Cell therapy for patients who have intractable muscle disorders may require highly regenerative cells from young, healthy allogeneic donors. Mesenchymal stem cells are currently under clinical investigation because they are known to induce muscle ...
Sunyoung Joo, Hyun Ju Lim, John D Jackson, Anthony Atala, James J Yoo   +4 more
doaj   +1 more source

RNA‐related functions of BRCA2 in transcription, replication, and genome stability

FEBS Letters, EarlyView.
Beyond its role in homologous recombination, BRCA2 regulates R‐loop homeostasis, DNA–RNA hybrid resolution, RNA polymerase II dynamics, and transcriptional activation. Disruption of any of these functions can contribute to genome instability, inflammatory signaling, and tumorigenesis. BRCA2 is a central tumor suppressor protein best known for its roles
Lucia Alvaro‐Aranda, Sreerama Chaitanya Sridhara, Aura Carreira   +2 more
wiley   +1 more source

Alginate-encapsulated brain-derived neurotrophic factor–overexpressing mesenchymal stem cells are a promising drug delivery system for protection of auditory neurons

Journal of Tissue Engineering, 2020
The cochlear implant outcome is possibly improved by brain-derived neurotrophic factor treatment protecting spiral ganglion neurons. Implantation of genetically modified mesenchymal stem cells may enable the required long-term brain-derived neurotrophic ...
Jana Schwieger, Anika Hamm, Michael M. Gepp, André Schulz, Andrea Hoffmann, Thomas Lenarz, Verena Scheper   +6 more
doaj   +1 more source

Identification of regulatory factors for mesenchymal stem cell-derived salivary epithelial cells in a co-culture system. [PDF]

PLoS ONE, 2014
Patients with Sjögren's syndrome or head and neck cancer patients who have undergone radiation therapy suffer from severe dry mouth (xerostomia) due to salivary exocrine cell death.
Yun-Jong Park, Jin Koh, Adrienne E Gauna, Sixue Chen, Seunghee Cha   +4 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. [PDF]

, 2011
BACKGROUND: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a
Kolappan, Madhan, Thomas, David L, Andrew W Michell, Altmann, Daniel R., Richardson, Karen, Wheeler-Kingshott, Claudia AM, Karen Richardson, Thompson, Alan J., Shi L Luan, David L Thomas, Tozer, Daniel J, Webber, Daniel J., Rebecca S Samson, Siddharthan Chandran, Xiao-Ling He, Crawley, Charles, Compston, Alastair, Du, Ming-Qing, Alan J Thompson, Michell, Andrew W, Webber, Daniel J, Peter Connick, Kelly Barber, Barber, Kelly, Ming-Qing Du, Thompson, Alan J, Michael A Scott, Claudia AM Wheeler-Kingshott, Charles Crawley, Madhan Kolappan, Alastair Compston, Thomas, David L., Patani, Rickie, Wheeler-Kingshott, Claudia A. M., Tozer, Daniel J., Miller, David H, Scott, Michael A., Daniel J Tozer, He, Xiao-Ling, Miller, David H., Luan, Shi L, Daniel J Webber, Rickie Patani, Altmann, Daniel R, Samson, Rebecca S, David H Miller, Scott, Michael A, Chandran, Siddharthan, Luan, Shi L., Daniel R Altmann, Connick, Peter, Samson, Rebecca S., Michell, Andrew W., Chandran Siddharthan, Kolappan Madhan, Luan Shi L, Miller David H, Crawley Charles, Richardson Karen, Wheeler-Kingshott Claudia AM, Scott Michael A, Thompson Alan J, Webber Daniel J, Du Ming-Qing, Compston Alastair, Patani Rickie, Altmann Daniel R, Samson Rebecca S, He Xiao-Ling, Connick Peter, Tozer Daniel J, Michell Andrew W, Barber Kelly, Thomas David L   +73 more
core   +4 more sources